Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

Delayed Quote. Delayed  - 08/23 10:00:31 pm
59.86 USD   +1.01%
08/22 ALLIED MINDS : Given New Debt, Raises Funds For Drug Development
08/21 BRISTOL MYERS S : Fukoku Mutual Life Insurance Co Lowers stake in Br..
08/11DJBusiness Watch -- WSJ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Biocon, Bristol-Myers Squibb Sign Pact for Experimental Oral Insulin Drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/16/2012 | 05:26am CEST
   By Rumman Ahmed 
 

BANGALORE, India--Biocon Ltd. (532523.BY) Friday said it has entered into an agreement with Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) on a licensing deal for its experimental biopharmaceutical drug IN-105, which is an orally administered insulin.

Under the terms of the agreement, the New York-headquartered company will have the right to exercise an option to obtain a global license for IN-105 on the successful completion of mid-stage trials for the experimental drug by Biocon, the Indian company said in a statement.

Biocon, which develops biological treatments that use proteins manufactured in living cells, is India's largest biotechnology company by revenue.

It has been seeking alliances with other drug makers for further development of the experimental drug under a licensing agreement.

If Bristol-Myers Squibb decides to obtain the license for IN-105, the U.S. company will assume full responsibility for the development program, including all development and commercialization activities outside India, the statement said.

In return, Biocon will receive a license fee, potential payments when IN-105 achieves certain regulatory and commercial milestones, as well as royalties on commercial sales of IN-105 outside India, the statement added.

Biocon will retain exclusive rights to IN-105 in India.

Indian drug makers often seek to develop drugs in partnership with foreign companies because they can help finance costly and lengthy research. At the same time, global companies are keen to cooperate with Indian companies because of lower costs, the availability of skilled scientists in the South Asian country, as well as the prospect of adding new products to their portfolios.

Write to Rumman Ahmed at rumman.ahmed@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bristol Myers Squibb Co.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB CO
08/22 ALLIED MINDS : Given New Debt, Raises Funds For Drug Development
08/21 BRISTOL MYERS SQUIBB : Fukoku Mutual Life Insurance Co Lowers stake in Bristol-M..
08/18 BRISTOL MYERS SQUIBB : Study Results from Bristol-Myers Squibb Provide New Insig..
08/18 EIGER BIOPHARMACEUTICALS : Reports Second Quarter 2016 Financial Results
08/18 BRISTOL MYERS SQUIBB : Announces Top-Line Results from CheckMate -026, a Phase 3..
08/18 BRISTOL MYERS SQUIBB : New Glutamic Acid Study Findings Have Been Reported by In..
08/11 BRISTOL MYERS SQUIBB : Studies from Bristol-Myers Squibb Have Provided New Data ..
08/11 BRISTOL MYERS SQUIBB : Study Data from Bristol-Myers Squibb Update Understanding..
08/11 BRISTOL MYERS SQUIBB : An Application for the Trademark "AZENMI" Has Been Filed ..
08/11 BRISTOL MYERS SQUIBB : Patent Issued for Methods for the Preparation of HIV Atta..
More news
Sector news : Pharmaceuticals - NEC
08/23DJU.S. Lawmakers Plan Hearing Over Wave of Agriculture Mergers
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/23DJNew CFO Tops Off Shake-Up At Valeant -- WSJ
08/22DJValeant Names Zoetis Executive as Financial Chief--Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/23 Game Plan For The Week - Cramer's Mad Money (8/22/16)
08/22 Is The Sky Falling Only On Gilead?
08/19 Play Oncology To Play M&A In Big Pharma?
08/19 Profit From Bristol-Myers' Drug Failure And Increased Volatility
08/17 Slimmed-Down Big Pharma Starts Growing Again
Advertisement
Financials ($)
Sales 2016 18 890 M
EBIT 2016 4 944 M
Net income 2016 4 379 M
Debt 2016 1 249 M
Yield 2016 2,61%
P/E ratio 2016 22,92
P/E ratio 2017 19,79
EV / Sales 2016 5,31x
EV / Sales 2017 4,82x
Capitalization 99 015 M
More Financials
Chart BRISTOL-MYERS SQUIBB CO
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 68,8 $
Spread / Average Target 16%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..-12.98%99 015
JOHNSON & JOHNSON16.28%325 925
ROCHE HOLDING LTD.-12.26%219 531
NOVARTIS AG-9.97%213 663
PFIZER INC.8.71%211 327
MERCK & CO., INC.20.37%175 729
More Results